Axitinib (AG-013736)

Ronan Joseph Kelly, Olivier Rixe

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes increased tumor cell proliferation, survival and metasasis. Many antiangiogenic agents including multi-RTK inhibitors are either approved or are undergoing testing in clinical trials. Axitinib is a potent and selective inhibitor of VEGF RTK 1, 2, and 3. This chapter discusses the stucture of axitinib as well as its toxicities and drug interactions. Important preclinical and clinical data for axitinib are presented including findings from phase II studies in many tumor types including malignant melanoma and renal, pancreatic, thyroid, breast, lung and colorectal carcinomas. Ongoing phase III studies in pancreatic and metastatic renal cell carcinoma will ultimately define the therapeutic role of this targeted agent.

Original languageEnglish (US)
Title of host publicationSmall Molecules in Oncology
EditorsUwe Martens, Uwe Martens, Uwe Martens
Pages33-44
Number of pages12
DOIs
StatePublished - Feb 10 2010

Publication series

NameRecent Results in Cancer Research
Volume184
ISSN (Print)0080-0015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Axitinib (AG-013736)'. Together they form a unique fingerprint.

Cite this